Bonilla-Sepúlveda ÓA

Language: Spanish
References: 22
Page: 943-950
PDF size: 200.29 Kb.

ABSTRACT

Objective: To determine the existence of delays in the diagnosis and treatment of breast cancer in women treated in Medellin (Colombia), to explore the associated factors, and to describe sociodemographic and clinical characteristics.
Materials and Methods: Retrospective, observational and analytical cross-sectional study of 331 women with breast cancer in Medellin (Colombia) in the personal record of a surgeon. Delays in the patient, provider and total were considered, defined as the time elapsed greater than 90 days, 30 days and 30 days, respectively; Demographic, clinical, and paraclinical data were collected and analyzed using descriptive statistics.
Results: 98.6% of the women had health insurance; 80.1% (n= 265) presented total treatment delay, 76.1% (N= 270) had patient delay, and 78% (n=277) provider delay; In the bivariate analysis, significant associations were established between total delay and belonging to the subsidized regimen (OR= 1.17; 95% CI 1.06-1.29; p= 0.008).
Conclusion: Among the patients studied, important delays were found due to the responsibility of the patient and the provider, and a total delay to treatment significantly associated with belonging to the subsidized regimen.

REFERENCES

1. https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.

2. Breen N, Gentleman JF, Schiller JS. Update on mammographytrends: Comparisons of rates in 2000, 2005, and 2008.Cancer 2011; 117 (10): 2209-18. doi:10.1002/cncr.25679

3. Berry DA, Cronin KA, Plevritis SK, et al. Effect of screeningand adjuvant therapy on mortality from breast cancer.N Engl J Med 2005; 353 (17): 1784-92. doi:10.1056/NEJMoa050518

4. Bonilla Sepúlveda ÓA. Inequidades en la atención delcáncer de mama en Colombia: revisión sistemática. MedUPB 2022; 41 (1): 29-37. doi:10.18566/medupb.v41n1.a05

5. Ramirez A, Westcombe A, Burgess C, Sutton S, LittlejohnsP, Richards M. Factors predicting delayed presentationof symptomatic breast cancer: a systematic review.Lancet 1999; 353 (9159): 1127-31. doi:10.1016/S0140-

6. 6736(99)02142-X6. Barber MD, Jack W, Dixon JM. Diagnostic delay in breastcancer. Br J Surg. 2003; 91 (1): 49-53. doi:10.1002/bjs.4436

7. Unger-Saldaña K, Peláez-Ballestas I, Infante-Castañeda C.Development and validation of a questionnaire to assessdelay in treatment for breast cancer. BMC Cancer 2012; 12(1): 626. doi:10.1186/1471-2407-12-626

8. Richards MA, Westcombe AM, Love SB, Littlejohns P,Ramirez AJ. Influence of delay on survival in patientswith breast cancer: a systematic review. Lancet 1999; 353(9159): 1119-26. doi: 10.1016/s0140-6736(99)02143-1.

9. Macleod U, Mitchell ED, Burgess C, Macdonald S, RamirezAJ. Risk factors for delayed presentation and referral ofsymptomatic cancer: evidence for common cancers. BrJ Cancer 2009; 101 (Suppl 2): S92-S101. doi: 10.1038/sj.bjc.6605398

10. International Agency for Research on Cancer, WorldHealth Organization. Breast cancer screening. Lyon: IARCPress, 2002.

11. Kalager M, Haldorsen T, Bretthauer M, Hoff G, ThoresenSO, Adami HO. Improved breast cancer survival followingintroduction of an organized mammography screeningprogram among both screened and unscreened women:a population-based cohort study. Breast Cancer Res 2009;11 (4): R44. doi:10.1186/bcr2331

12. Jassem J, Ozmen V, Bacanu F, Drobniene M, Eglitis J, LakshmaiahKC, Kahan Z, Mardiak J, Pieńkowski T, SemiglazovaT, Stamatovic L, Timcheva C, Vasovic S, Vrbanec D, ZaborekP. Delays in diagnosis and treatment of breast cancer: amultinational analysis. Eur J Public Health 2014; 24 (5):761-7. doi: 10.1093/eurpub/ckt131

13. Buzdar AU, Smith TL, Powell KC, Blumenschein GR, GehanEA. Effect of timing of initiation of adjuvant chemotherapyon disease-free survival in breast cancer. Breast Cancer ResTreat 1982; 2 (2): 163-9. doi: 10.1007/BF01806452

14. Piñeros M, Sánchez R, Perry F, García OA, Ocampo R, CendalesR. Delay for diagnosis and treatment of breast cancer inBogotá, Colombia. Salud Publica Mex 2011; 53 (6): 478-85.

15. Charry LC, Carrasquilla G, Roca S. Equidad en la deteccióndel cáncer de seno en Colombia [Equity regarding earlybreast cancer screening according to health insurancestatus in Colombia]. Rev Salud Publica (Bogota) 2008;10 (4): 571-82. doi:10.1590/s0124-00642008000400007

16. https://consultorsalud.com/panorama-del-cancer-demama-en-colombia-2020/.

17. Sánchez G, Niño CG, Estupiñán C. Factores asociados conel tratamiento oportuno en mujeres con cáncer de mamaapoyadas por una organización no gubernamental enBogotá. Biomédica 2015; 35 (4). doi:10.7705/biomedica.v35i4.2378

18. Duarte C, Salazar A, Strasser-Weippl K, et al. Breast cancerin Colombia: a growing challenge for the healthcare system.Breast Cancer Res Treat 2021; 186 (1): 15-24. doi:10.1007/s10549-020-06091-6

19. Egurrola-Pedraza JA, Gómez-Wolff LR, Ossa-Gómez CA,Sánchez-Jiménez V, Herazo-Maya F, García-García HI.Diferencias en supervivencia debidas al aseguramientoen salud en pacientes con cáncer de mama atendidasen un centro oncológico de referencia en Medellín, Colombia.Cad Saúde Pública 2018; 34 (12): e00114117.doi:10.1590/0102-311x00114117

20. Martínez-Pérez DC, Gómez-Wolff LR, Ossa-Gómez CA,Hernández-Herrera GN, Rivas-Bedoya Y, García-García HI.Asociación entre retraso en el diagnóstico y estadio clínicoavanzado de cáncer de mama al momento de la consulta encuatro centros oncológicos de Medellín, Colombia, 2017.Rev Colomb Obstet Ginecol 2020; 71 (2). doi:10.18597/rcog.3410

21. Huerta-Gutiérrez R, Murillo-Zamora E, Ángeles-LlerenasA, Ortega-Olvera C, Torres-Mejía G. Patient and treatmentdelays among Mexican women with breast cancer beforeand after the Seguro Popular. Salud Pública México 2021:87-95. doi:10.21149/12472

22. Martínez R, Susan P, Segura C, Ángela R, Arias V, SamuelA, Mateus L Gilbert. Caracterización de los tiempos deatención y de mujeres con cáncer de mama que asistierona un hospital de tercer nivel, 2005-2009. Rev Fac Nac SaludPública 2012; 30 (2): 183-91.